PROFILPELAJAR.COM

YC8-02

YC8-02
Clinical data
Drug classSIRT2/3 inhibitor
Identifiers
  • 2-[[(2S)-1-(3-hydroxyanilino)-1-oxo-6-(tetradecanethioylamino)hexan-2-yl]amino]ethyl-triphenylphosphanium
PubChem CID
ChEMBL
Chemical and physical data
FormulaC46H63N3O2PS
Molar mass753.06 g·mol−1
3D model (JSmol)
  • CCCCCCCCCCCCCC(=S)NCCCC[C@@H](C(=O)NC1=CC(=CC=C1)O)NCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4
  • InChI=1S/C46H62N3O2PS/c1-2-3-4-5-6-7-8-9-10-11-21-34-45(53)48-35-23-22-33-44(46(51)49-39-25-24-26-40(50)38-39)47-36-37-52(41-27-15-12-16-28-41,42-29-17-13-18-30-42)43-31-19-14-20-32-43/h12-20,24-32,38,44,47H,2-11,21-23,33-37H2,1H3,(H2-,48,49,50,51,53)/p+1/t44-/m0/s1
  • Key:RIVWUGLXBPHZGR-SJARJILFSA-O

YC8-02 is a drug which acts as a potent inhibitor of the enzymes sirtuin 2 (SIRT2) and sirtuin 3 (SIRT3). It was developed from an older SIRT2 selective inhibitor thiomyristoyl, but substituted with a triphenylphosphine group which increases affinity to SIRT3 and selectively targets uptake into mitochondria. It is still relatively selective for SIRT2 with an IC50 of 62nM at SIRT2 vs 530nM at SIRT3, but this still makes it one of the most potent SIRT3 inhibitors currently available. In animal studies it is useful for the treatment of certain forms of blood cancer such as lymphoma and leukemia.[1][2][3]

See also

References

  1. ^ Li M, Chiang YL, Lyssiotis CA, Teater MR, Hong JY, Shen H, et al. (June 2019). "Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis". Cancer Cell. 35 (6): 916–931.e9. doi:10.1016/j.ccell.2019.05.002. PMC 7534582. PMID 31185214.
  2. ^ Jana S, Shang J, Hong JY, Fenwick MK, Puri R, Lu X, et al. (September 2024). "A Mitochondria-Targeting SIRT3 Inhibitor with Activity against Diffuse Large B Cell Lymphoma". Journal of Medicinal Chemistry. 67 (17): 15428–15437. doi:10.1021/acs.jmedchem.4c01053. PMID 39191393.
  3. ^ O'Brien C, Ling T, Berman JM, Culp-Hill R, Reisz JA, Rondeau V, et al. (September 2023). "Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity". Haematologica. 108 (9): 2343–2357. doi:10.3324/haematol.2022.281894. PMID 37021547.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.